Table 1

Effect of 5 μm PDMP and 2 μm C6-Cer on anticancer drug cytotoxicity in wt and multidrug-resistant MCF7 and MDA435/LCC6 breast cancer cells

Cell lineIC50a ± SE
TaxolVincristineDoxorubicinCisplatin
MCF712.52 ± 3.64 nm0.76 ± 0.18 nm0.17 ± 0.06 μm33.99 ± 3.29 μm
MCF7 + PDMP12.08 ± 0.11 nm0.77 ± 0.16 nm0.18 ± 0.07 μm34.38 ± 4.55 μm
MCF7/AdrR3.24 ± 0.06 μm11.02 ± 2.16 μm0.34 ± 0.12 μm27.57 ± 9.08 μm
MCF7/AdrR + PDMP0.50 ± 0.20 μm1.82 ± 0.16 μm0.34 ± 0.12 μm28.75 ± 12.52 μm
MCF7/AdrR + PDMP + C6-Cer0.68 ± 0.08 μm1.48 ± 0.01 μmN/DbN/D
MDA435/LCC61.81 ± 1.37 nm0.22 ± 0.02 nm0.25 ± 0.14 μm10.17 ± 3.57 μm
MDA435/LCC6 + PDMP1.27 ± 1.06 nm0.18 ± 0.02 nm0.23 ± 0.16 μm9.95 ± 5.02 μm
MDA435/LCC6MDR130.01 ± 4.13 nm39.25 ± 7.90 nm3.87 ± 1.57 μm14.25 ± 1.06 μm
MDA435/LCC6MDR1 + PDMP2.21 ± 1.14 nm1.04 ± 0.40 nm3.41 ± 1.51 μm14.25 ± 1.06 μm
MDA435/LCC6MDR1 + PDMP + C6-Cer2.40 ± 1.97 nm41.18 ± 0.38 nmN/DN/D
  • a Cells were incubated with increasing drug concentrations ± 5 μm PDMP and 2 μm C6-Cer over 72 h, and viability was analyzed by the MTT assay. The IC50 value was taken as the anticancer drug concentration that inhibits cell growth by 50% relative to untreated control cells.

  • b N/D, not determined.